Literature DB >> 10933056

BRCA1 partially reverses the transforming activity of the ras oncogene.

A Kumar1, C Knott, K Kuus-Reichel, M S Saedi.   

Abstract

The BRCA1 gene is associated with hereditary breast and ovarian cancers. BRCA1 fits the model of a classic tumor suppressor gene, a hypothesis supported by recent work demonstrating that expression of BRCA1 inhibits growth of breast and ovarian cancer cell lines. The present study was designed to test the potential of BRCA1 to reverse the transforming activity of the ras oncogene. The v-Ha ras oncogene was cloned downstream of the retrovirus LTR and stably expressed in Rat-1 cells (Rat-1/ras). Rat-1/ras (R/R) cells were fully transformed as indicated by change in morphology, colony formation in soft-agarose and tumor induction in nude mice. BRCA1 was stably expressed in R/R cells under the CMV promoter (R/R-BRCA1). The expression of ras and BRCA1 was confirmed by Western blot using monoclonal antibodies (mAbs) specific to ras and BRCA1, respectively. R/R-BRCA1 cells grew slower than the negative control, which was R/R cells transfected with vector alone (R/R-pCEP4). R/R-BRCA1 cells generated approximately 5 to 10 times less colonies in a soft-agarose assay compared to the negative control. When injected into nude mice, R/R-BRCA1 cells exhibited a delayed onset of tumorigenesis and generated smaller tumors compared to R/R or R/R-pCEP4 cells. These data strongly suggest that BRCA1 partially reverses the transforming activity of the v-Ha ras oncogene indicating that BRCA1 can bypass the effects of the v-Ha ras oncogene on cell growth. BRCA1, therefore, may be used in therapy of tumors arising due to activation of v-Ha ras oncogene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10933056      PMCID: PMC1508109          DOI: 10.1038/sj.neo.7900058

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  24 in total

Review 1.  Transforming collaborations between ras and nuclear oncogenes.

Authors:  H E Ruley
Journal:  Cancer Cells       Date:  1990 Aug-Sep

2.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

3.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.

Authors:  M E Thompson; R A Jensen; P S Obermiller; D L Page; J T Holt
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

4.  Transformation of primary rat embryo cells.

Authors:  H Land
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

5.  The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.

Authors:  R Hakem; J L de la Pompa; C Sirard; R Mo; M Woo; A Hakem; A Wakeham; J Potter; A Reitmair; F Billia; E Firpo; C C Hui; J Roberts; J Rossant; T W Mak
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

6.  Induction of apoptosis by the tumor suppressor protein BRCA1.

Authors:  N Shao; Y L Chai; E Shyam; P Reddy; V N Rao
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

7.  Growth retardation and tumour inhibition by BRCA1.

Authors:  J T Holt; M E Thompson; C Szabo; C Robinson-Benion; C L Arteaga; M C King; R A Jensen
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

Review 8.  Inherited breast and ovarian cancer.

Authors:  C I Szabo; M C King
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

9.  Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.

Authors:  V N Rao; N Shao; M Ahmad; E S Reddy
Journal:  Oncogene       Date:  1996-02-01       Impact factor: 9.867

10.  Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells.

Authors:  K Kuus-Reichel; C Knott; P Sam-Fong; E Petrella; J R Corvalan
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.